CTP-499, invented using Concert’s DCE Platform (deuterated chemical entity platform), is a potential first-in-class treatment for chronic kidney disease.
It is a deuterium containing new chemical entity which was derived from an active metabolite of a drug approved for a different indication.
As per formulation studies CTP-499 has the potential to protect kidney function and slow disease progression when added to existing therapy.
Concert Pharmaceuticals CEO president Roger Tung said they are excited about the progress of CTP-499 and its potential to treat diabetic nephropathy and more generally chronic kidney disease.
"We look forward to advancing CTP-499 in clinical testing to evaluate its benefits in the treatment of diabetic nephropathy and other forms of chronic kidney disease," Tung said.